Just a few months after Vitra Bioscience closed shop due to a dearth of venture capital, Serologicals will buy its flagship CellCard technology for conducting miniaturized and multiplexed cell-based high-content assays, according to a former Vitra executive as well as a Serologicals official.

The acquisition fits with Serologicals' recent entry into the cell-based assay and high-content screening arena through the partnership it announced earlier this month with HCS reagent and service firm Cellumen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.